Fiche société
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Traitements, essais et publications liés.
Traitements6programmes
Essais5liés
Publications0liées
SourceDBlocale
Traitements
6| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| KarXTThe purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease | Alzheimer | Phase 3 | À vérifier | United States, Belgium, Canada, Chile, China, Greece, Hungary, Mexico, … | À vérifier |
| KarXTThe purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease | Alzheimer | Phase 3 | À vérifier | United States, Argentina, Australia, Brazil, Finland, France, Germany, Greece, Italy, Japan, Netherlands, Poland, Portugal, Puerto Rico, Romania, Spain, United Kingdom | À vérifier |
| KarXTThe purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease | Alzheimer | Phase 3 | À vérifier | United States, Argentina, Belgium, Brazil, Bulgaria, China, Croatia, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Poland, Portugal, Puerto Rico, Romania, Serbia, … | À vérifier |
| KarXTThe purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease | Alzheimer | Phase 3 | À vérifier | United States, Belgium, Canada, Chile, China, Greece, Hungary, Mexico, Peru, Poland, South Korea, Switzerland, Turkey (Türkiye), United Kingdom | À vérifier |
| KarXTThe purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease | Alzheimer | Phase 3 | À vérifier | United States, Argentina, Belgium, Brazil, Bulgaria, Canada, Chile, China, Croatia, Czechia, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Mexico, Peru, … | À vérifier |
| KarXTThe purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease | Alzheimer | Phase 3 | À vérifier | United States, Argentina, Brazil, Bulgaria, Canada, Chile, China, Croatia, Czechia, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Mexico, Poland, Portugal, … | À vérifier |
Essais cliniques
5| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| KarXT | Alzheimer | Phase 3 | NCT06937229 | A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) | RECRUITING |
| KarXT | Alzheimer | Phase 3 | NCT05980949 | Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | RECRUITING |
| KarXT | Alzheimer | Phase 3 | NCT06126224 | A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2) | RECRUITING |
| KarXT | Alzheimer | Phase 3 | NCT06585787 | A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | RECRUITING |
| KarXT | Alzheimer | Phase 3 | NCT06976203 | A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2) | RECRUITING |
Publications
0| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Aucune publication. | ||||